Aytu BioPharma (AYTU) Fiscal Q4 2026 Earnings Call: EXXUA Growth and FY2027 Outlook
Source Tradingkey
Key Takeaways
- Aytu BioPharma reported fiscal Q4 2026 net revenue of $16.1 million, up 6% year over year and from $12.4 million in fiscal Q3. Full-year net revenue was $57.6 million.
- EXXUA generated $3.9 million of Q4 net revenue, up from $2.4 million in Q3. Quarterly prescriptions rose to 3,323 from 1,398, while 4,599 units were shipped.
- The company returned to positive quarterly adjusted EBITDA of $0.5 million, versus a $2.8 million loss in Q3. Q4 net loss narrowed to $0.1 million.
- Cash remained relatively stable at $26.3 million as of June 30, 2026, despite debt reduction. Aytu generated $3.3 million of operating cash flow for fiscal 2026 and subsequently repaid the remaining revolving credit balance.
- Management expects fiscal 2027 GAAP operating expenses of $49 million to $54 million and cash-based operating expenses of $45 million to $49 million. It expects the six months ending June 30, 2027, to generate positive adjusted EBITDA.
- EXXUA prescriptions continued rising after quarter-end, reaching 1,377 in July, 1,408 in August, and a weekly record of 394 for the week ended September 4.
Key Financial Data
| Metric | Fiscal Q4 2026 | Comparison / context |
|---|---|---|
| Net revenue | $16.1 million | Up 6% from $15.1 million a year earlier; Q3 was $12.4 million |
| EXXUA net revenue | $3.9 million | Up from $2.4 million in Q3 |
| ADHD portfolio revenue | $10.4 million | $13.1 million a year earlier; $9.1 million in Q3 |
| Pediatrics revenue | $1.8 million | $2.0 million a year earlier; $0.9 million in Q3 |
| Gross profit | $10.4 million | $10.3 million a year earlier |
| Gross margin | Approximately 65% | 68% a year earlier and 61% in Q3 |
| Operating expenses | $11.2 million | $17.9 million a year earlier, including an $8.3 million prior-year impairment charge |
| Net loss | $0.1 million | $19.8 million loss a year earlier |
| Adjusted EBITDA | $0.5 million | $2.0 million a year earlier; negative $2.8 million in Q3 |
| Cash and cash equivalents | $26.3 million | $26.7 million at March 31 and $31.0 million at fiscal 2025 year-end |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
SpaceX stock rose 5.89% to $151.94 on Wednesday morning after the company set September 22 for Starship Flight 14, the rocket’s first attempt to reach orbit.That pushed its market value to above $2 tr
USD/JPY remains under pressure as the Japanese yen strengthens ahead of another potentially important Bank of Japan policy decision. The pair has fallen toward the mid-155 region after breaking below
Benjamin Cowen, founder of Into The Cryptoverse, publicly admitted his bearish Bitcoin call failed on Monday, as the cryptocurrency broke decisively above $85,000 and squeezed short sellers.The revers
Goldman Sachs pushed back hard against fears of an S&P 500 earnings bubble on Tuesday. The firm projects another quarter of double-digit growth starting next week.Deutsche Bank echoed that confidence
Bitcoin (BTC) traded at $86,423 on Tuesday, up from below $76,000 a week ago. Tom Lee and iTrustCapital’s CEO, Kevin Maloney, say the worst is now behind investors.Both men made their case after a US
